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ABSTRACT
Introduction: To determine the feasibility,
maximum-tolerated dose (MTD), and
dose-limiting toxicities (DLT) of pazopanib in
combination with cisplatin.
Methods: Patients with advanced malignancies
were included in a 3 ? 3 dose-escalation phase I
study. Pazopanib administration started 8 days
before the first infusion of cisplatin; some
patients were treated according to a reverse
sequence (cisplatin first). Five dose levels (DLs)
were planned. MTD was based on DLT observed
during cycles 1 and 2.
Results: Thirty-five patients were enrolled. The
MTD was reached at the first DL, (pazopanib
400 mg daily ? cisplatin 75 mg/m2 every
21 days). Main DLTs were pulmonary
embolism, neutropenia, thrombocytopenia,
and elevation of liver enzymes. Overall, most
common adverse events were anemia (83%),
fatigue (80%), thrombocytopenia (80%),
neutropenia (73%), hypertension (59%),
neurotoxicity (56%), and anorexia (53%).
Sixteen patients (46%) discontinued the study
due to toxicity. One patient (sarcoma) had a
complete response, and three patients (one with
breast cancer and two with ovarian cancers) had
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a partial response. Pharmacokinetic (PK)
analyses showed interactions with aprepitant,
resulting in increased exposure to pazopanib,
which might explain partly the poor tolerance
of the combination.
Conclusion: Cisplatin and pazopanib could not
be administered at their single agent full doses,
partly due to a PK interaction between
pazopanib and aprepitant.
Funding: This work was funded by
GlaxoSmithKline and by the charity Ligue
Nationale de Lutte Contre le Cancer.
Trial registered: ClinicalTrials.gov identifier,
NCT01165385.
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INTRODUCTION
Therapeutic options are limited in advanced or
refractory malignancies. The addition of
angiogenesis inhibitors to cytotoxic drugs
could enhance antitumor activity. Moreover,
anti-angiogenic agents may normalize ‘‘leaky’’
tumor vasculature and increase the delivery of
chemotherapy agents to the tumor site and
enhance their efficacy [1]. The combination of
chemotherapy and angiogenesis inhibition is
already approved in some tumor types, using
the anti-vascular endothelial growth factor
(VEGF) monoclonal antibody bevacizumab.
Bevacizumab has shown progression free
survival benefits in ovarian cancer [2],
colorectal cancer [3], non-small cell lung
cancer (NSCLC) [4], breast cancer [5], and
overall survival benefit in cervical cancer [6].
Preclinical data suggested that anti-angiogenic
agents targeting multiple tyrosine kinases might
have better anti-tumor activity [7].
Pazopanib is an orally active multi-targeted
tyrosine kinase inhibitor of VEGFR-1, 2, and 3,
platelet derived growth factor receptor a and b,
fibroblast growth factor receptor 1 and 3, and
c-Kit. It has been approved for the treatment of
advanced renal cell carcinoma and advanced
soft tissue sarcomas at a dose of 800 mg daily.
Tested as a single agent in several phase II
studies, pazopanib has also demonstrated
efficacy in various types of solid tumors, such
as metastatic differentiated thyroid cancers [8],
medullary thyroid carcinoma [9],
gastroenteropancreatic neuroendocrine tumors
[10], and recurrent/metastatic breast cancer
treated with up to two prior lines of
chemotherapy [11].
Several combinations of pazopanib and
chemotherapy have been investigated in
clinical trials, using gemcitabine [12],
pemetrexed [13, 14], paclitaxel [15, 16],
paclitaxel and carboplatin [17], paclitaxel and
lapatinib [18], docetaxel [19] or ixabepilone
[20]. For triple negative breast cancer, where no
targeted treatment is approved, recent data
favor an activity of platinum salts and a
positive impact of anti-angiogenic treatment
[5]. Platinum salts are major cytotoxic agents,
used in various types of advanced tumors. The
feasibility of combining cisplatin with
pazopanib was investigated in a phase I,
open-label, dose-escalation, and
pharmacokinetic (PK) study, to determine the
dose-limiting toxicities (DLT) and the
maximum tolerated dose (MTD) in patients
with recurrent or refractory solid malignancies.
METHODS
Eligibility Criteria
Eligible patients were C18 year old, had locally
advanced, unresectable or metastatic, and
histologically confirmed malignant solid
tumors, progressing on standard therapy or for
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whom no standard therapy was available, and
candidates for a platinum-based chemotherapy.
In the case of breast cancer, patients were
eligible if they had received anthracyclines
and taxanes for HER2-/HR (hormone
receptor)- tumors, anthracyclines, taxanes,
and capecitabine for HER2-/HR? tumors.
Other inclusion criteria were Eastern
Cooperative Oncology Group performance
status of 0 or 1, adequate hematologic,
coagulation and liver function, negative
dipstick proteinuria test or positive proteinuria
\1 g/24H, creatinine clearance[60 ml/mn, and
left ventricular ejection fraction (LVEF) [50.
Patients were excluded if they had
HER2 ? breast cancers, uncontrolled brain
metastases, poorly controlled hypertension,
peripheral neuropathy more than grade (G) 1,
any conditions affecting gastrointestinal
functions, high risk of bleeding or
anticoagulant therapy, concomitant
antineoplastic treatment, previous cisplatin
therapy with a cumulated dose C300 mg/m2,
or any concomitant treatment with cytochrome
P450 3A4 (CYP3A4) inhibitors or inductors.
Study Design
This was a phase I, multi-center, open-label
dose-finding study, exploring PK interactions
and using a 3 ? 3 enrollment design with a
planned expansion at the MTD. In the initial
sequence, pazopanib administration (oral
morning daily intake in fasted condition)
started 8 days before adding cisplatin
[intravenously every 3 weeks (q3W)] on day 1
(Fig. 1). Predefined dose levels are shown in
Table 1. After 22 patients had been included
and the observation of early DLTs, the Data
Safety Monitoring Board hypothesized that the
unexpected toxicity of the combination might
be due to potential interactions of pazopanib on
cisplatin PK. Consequently, a reverse sequence
(RS) with cisplatin given first (q3W) and
pazopanib starting on day 8 (daily) was added
after amendment to the protocol, using the
Fig. 1 Treatment regimens and sequences. a Initial sequence. b Reverse sequence: cisplatin administered before pazopanib
(cycle 1) and after 14-day pazopanib (cycle 2). IV intravenous,q3W every 3 weeksand PO per os
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MTD doses (Fig. 1). The DLT period was 42 days,
encompassing cycles 1 and 2. The MTD was
defined as the maximal dose regimen for which
less than one-third of patients experienced DLT
during the DLT period, when at least six
evaluable patients had received this regimen
[i.e., 0 or 1 patients out of six experienced DLT
in this dose level (DL)]. Treatment was pursued
until unacceptable toxicity or disease
progression.
Due to the high emetogenic potential of
cisplatin, all patients received antiemetic
comedications: aprepitant 125 mg given orally,
methyl prednisolone 80 mg iv, and granisetron
3 mg iv on day 1; aprepitant was continued on
days 2 and 3 at 80 mg per day. An interaction
between aprepitant and pazopanib was
expected. In the case of toxicity, dose
modification guidelines were predefined for
cisplatin and/or pazopanib.
Assessments
Screening assessments were performed within
28 days before study entry and included clinical
and laboratory examinations, cardiac
echography or multi-gated acquisition scan
with measurement of LVEF, and imaging
[computed tomography (CT) scan and/or
magnetic resonance imaging (MRI)]. At the
beginning of each cycle, patients underwent
an updated history, physical examination,
electrocardiogram, and thyroid function,
hematology, and chemistry laboratory
assessments.
Toxicity was graded according to the
National Cancer Institute Common
Terminology Criteria for Adverse Events,
version 4.03. Toxicity assessments were
performed weekly during the first two cycles,
and on day 1 of each 21-day cycle thereafter.
The determination of DLT was based on
tolerance during cycles 1 and 2 and defined as
follows: G4 neutropenia lasting more than
7 days, febrile (C38.5 C) G3–4 neutropenia,
G4 or symptomatic G3 thrombocytopenia,
uncontrolled high blood pressure (HBP),
despite pazopanib interruption [2 weeks,
symptomatic HBP, 2 or more symptomatic
episodes of HBP despite dose adjustment of
pazopanib and antihypertensive treatment,
confirmed LVEF decrease (relative decrease
C20% and LVEF below lower limit of normal),
proteinuria [3 g/24H, G2 neuropathy for at
least 7 days or G3 neuropathy, any G3–4
non-hematological toxicity, excluding fatigue,
anorexia, nausea, vomiting and diarrhea, if
considered clinically significant and
drug-related by the investigator, inability to
administer the planned dose of pazopanib more
than 2 weeks in one cycle, delay C2 weeks for
the second cisplatin administration.
Blood samples were collected for PK
evaluation, and a population PK analysis was
performed as previously described [21]. Imaging
(CT scan or MRI) for efficacy assessment was to
be performed every two cycles or sooner if
clinically indicated.
Table 1 Predeﬁned dose levels for cisplatin and pazopanib












DL1 reverse sequencea 75 400
a DL added during the trial
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Statistics
The primary objective of the study was to
identify the MTD, based on the rate of DLT
occurring during cycles 1 and 2. Patients who
progressed before the end of cycle 2 without
evidence of DLT were considered not evaluable
for the primary objective analysis and replaced
during the dose-escalation part. All patients
who received at least one dose of either study
agent(s) were included in the safety analysis. To
be evaluable for DLT, a patient was to be
observed for the first two cycles of
chemotherapy or to have experienced DLT.
Secondary end points included PK profile of
the combination and antitumor activity
assessed by RECIST criteria version 1.1. Only
descriptive statistics were used, with mean,
standard error, median, ranges, quartiles for
quantitative variables and counts, and
percentages for categorical variables (analyses
conducted with SAS version 9.1, SAS Institute
Inc, Cary, NC, USA).
Compliance with Ethics Guidelines
This study was conducted in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013, in Good Clinical Practices and in
European Directive 2001/20/CE regarding the
conduct of clinical trials. The study was
approved by an independent ethics committee
(CPP Ile de France I) and the French National
Health Authorities (ANSM). The study was
registered in ClinicalTrials.gov (NCT01165385)
database. All patients gave written informed
consent before participating in the trial.
RESULTS
In total, 35 patients were included at five
sites, from July 2010 to September 2013.
Twenty-six were treated according to the
initial sequence and 9 according to the
reverse sequence (DL1RS), i.e., 75 mg/m2 of
cisplatin first and 400 mg of pazopanib. The
safety and DLT evaluable populations
comprised 34 and 29 patients, respectively.
Baseline characteristics of patients, tumors,
and prior chemotherapy are summarized in
Table 2. Among previous treatments, 32
(91%) patients had undergone surgery, 20
(57%) radiation therapy, and 4 (11%)
endocrine therapy. All patients had received
prior chemotherapy/targeted therapies except
the 4 patients with head and neck cystic
adenoid carcinoma.
The patients received a median number of 3
(0–8) cycles with cisplatin and 3 (0–28) cycles
with pazopanib. The cisplatin dose was reduced
at least once in 8 patients (23%) in DL1, 2 and
1RS. Thirteen patients had to discontinue
cisplatin (including four in DL2 and 5 in DL1
RS), and seven patients had to discontinue
pazopanib (four patients had to discontinue
both cisplatin and pazopanib). After
discontinuation of cisplatin (either for toxicity
or cumulative dose), six patients continued
pazopanib alone.
During DL1, 1 DLT occurred [G3 alanine
aminotransferase (ALT) elevation] among three
evaluable patients. However, G3 anemia and
pulmonary embolism occurred in the same slot
of patients, and even if they were not
accounted as DLT, those toxicities were
considered for the management of the dose
level. Consequently, in a safe approach, DSMB
decided to explore the lower level (DL-1)
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before expanding DL-1 to 3 other patients. No
DLT occurred in DL-1.
To better evaluate potential interactions of
cisplatin on pazopanib, an additional not
preplanned DL-2 was explored. The cisplatin
dose was maintained at 75 mg/m2 for efficacy
reasons and pazopanib reduced to 200 mg/day
to minimize toxicity. No DLT were observed. PK
results showed an increase in pazopanib area
under curve (AUC) when the drug was taken the
days of aprepitant administration. These
increases in pazopanib AUC revealed a
decrease of pazopanib oral clearance (CL/F
with CL for pazopanib clearance, and F for
oral pazopanib bioavailability).
After DL-1 and DL-2 were considered safe,
DL1 was reopened while the protocol was
amended with more restrictive inclusion
criteria (B2 lines of chemotherapy in
metastatic setting, no history of anemia or
thrombocytopenia CG3), to exclude patients
with the highest risks of toxicity. DL1RS was
then open at MTD to investigate potential
interactions of pazopanib on cisplatin PKs that
were not considered at the study initiation.
DL1RS was considered safe with 1 DLT over 9
evaluable patients. In total, among 29 evaluable
patients, 5 experienced at least one DLT: 1 in
DL1, 3 in DL2, and 1 in DL1RS (Table 3).
Reported DLT was G3 ALT elevations (n = 2),
G3 pulmonary embolism (n = 2), G4
hyponatremia (n = 1), G3 thrombocytopenia
(n = 2), and G3 neutropenia (n = 2). DL1, i.e.,
pazopanib 400 mg daily (qd) combined with
cisplatin 75 mg/m2 q3W was identified as the
MTD. Considering the toxicity profile observed
in all dose levels, the DSMB decided to not
expand the cohort and not explore this
combination in a phase II trial in advanced
triple negative breast cancer.
Table 2 Baseline characteristics of patients and tumors
Variables Total (n5 35)
Gender (male) 13 (37%)
Age (years)
Median (min–max) 59 (24–72)
Weight (kg)







H&N cystic adenoid carcinoma 5 (14%)
Colorectal 4 (11%)
Breast 4 (11%)
Uveal melanoma 3 (9%)
Endometrial carcinoma 1 (3%)
Liver 1 (3%)
Lung 1 (3%)




Naı¨vea 4 (11 %)
B2 Lines 23 (66 %)
[2 Linesb 8 (23 %)
Prior cisplatin 6 (17 %)
Cumulated dose of prior cisplatin mg/m2
Median (min–max) 172.5 (75; 239)
H&N Head and neck, ECOG Eastern Cooperative
Oncology Group, DL dose level, RS reverse sequence
a All cystic adenoid carcinoma patients
b Five patients treated in DL1, 2 in DL-2, 1 in DL1RS
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Most frequent adverse events (all grades)
were myelotoxicity (anemia 83%, neutropenia
73%, and thrombocytopenia 80%), fatigue
(80%), and hypertension (59%) (Table 4). G3–4
adverse events were reported in more than 10%
of patients for neutropenia (35%), hypertension
(21%), fatigue (18%), anemia (15%), and
thrombocytopenia (15%).
At the cut-off date, one patient was still
treated (desmoid tumor with complete
response). Reasons for discontinuation in the
remaining 34 patients were
unacceptable toxicity in 16 cases (46), tumor
progression in 17 patients (50%) and switch to
another antitumor therapy in 1 patient (3%).
Overall, 19 patients died, all from disease
progression. The median duration of follow-up
after the end of treatment was 9 months (1–20).
Four patients had an objective response,
including one complete response (one patient
with sarcoma) and three partial responses (two
patients with ovarian cancer, including one
[6 months, and one patient with breast
cancer).Twenty patients experienced a
stable disease (including one[6 months).
PK results have been published elsewhere
[21]. Mean [coefficient of variation (CV%) for
inter-individual variability] cisplatin clearance
was 10.3 L/h (33%) and appeared not
influenced by pazopanib. However, pazopanib
PKs was significantly modified by the cisplatin
regimen (most likely due to an interaction of
aprepitant on pazopanib metabolism). Mean
(CV%) of oral pazopanib clearance was 0.66 L/h
(55%) at day 0 (before cisplatin administration),
25% lower at day 1, and 33% lower at day 2.
This interaction is less likely due to cisplatin
than to a competitive inhibition of pazopanib
metabolism and efflux by aprepitant,
systematically combined with cisplatin.
Moreover, the plasma pazopanib exposures
observed at day 0 (before cisplatin
administration) with a 400-mg dose were
similar to those observed at the recommended








-2 3 ? 1NEa 75 200 3 0
-1 3 60 400 2 0
1 3 ? 3NEa 75 400 1 1 One patient with G3 ALT elevation and
G3 pulmonary embolism3 ? 2NEa 4
2 6
2 5 ? 1NEa 75 600 5 3 Two patients with G3
thrombocytopenia ? G3 neutropeniab
One patient with G4 hyponatremia ? G3
ALT elevation
1 RS 9 75 400 7 1 One patient with G3 pulmonary embolism
G grade, ALT alanine aminotransferase, RS reverse sequence
a Non evaluable for DLT
b Resulting in[2 weeks delay in C2 cisplatin administration
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dose of pazopanib in mono-chemotherapy
(800 mg) during the first-in-man phase I study
[23].
DISCUSSION
In this study, we assessed the feasibility and the
MTD of pazopanib plus cisplatin, a
combination that has the potential for
providing therapeutic benefits in patients with
recurrent/refractory tumors, due to the addition
of anti-angiogenic effects to chemotherapy.
Main toxicities were myelosuppression,
fatigue, and hypertension, consistent with the
known toxicity profile of both drugs. It has
been shown that the addition of tyrosine kinase
inhibitors (TKI) significantly increases toxicity
compared to chemotherapy alone, especially
myelosuppression, fatigue, skin toxicity,
hypertension, and diarrhea [22]. Since no
previous study assessed the combination of
cisplatin and pazopanib, the starting doses
were chosen below those used in
monotherapy. In addition, DLT were evaluated
over cycles 1 and 2 to observe cumulative
toxicities as suggested for targeted agents [23].
The common metabolism of pazopanib and
aprepitant was known, and interactions
between both drugs were expected. We
observed a poor tolerance from the first dose
level that corresponded to the MTD, namely,
pazopanib 400 mg daily and cisplatin 75 mg/
m2 q3W. DLTs were elevations of liver enzymes,
pulmonary embolism, and myelosuppression.
Table 4 Most frequent adverse events across dose-level groups (% of patients)
DL-2, n5 4 DL-1, n 5 3 DL1, n5 12a DL2, n5 6 DL1RS, n5 9 Total, n5 34
G1–2 G3–4 G1–2 G3–4 G1–2 G3–4 G1–2 G3–4 G1–2 G3–4 G1–2 G3–4
Anemia 75 25 100 0 50 25 67 0 78 11 68 15
Neutropenia 25 50 67 0 42 17 33 50 33 56 38 35
Thrombocytopenia 50 25 67 0 67 9 50 33 44 11 65 15
Anorexia 50 0 33 0 50 17 33 0 44 11 44 9
Vomiting 25 0 67 0 50 0 17 17 56 0 44 3
Renal failure 0 0 0 0 0 0 17 17 22 0 9 3
LVEF decrease 25 0 0 0 0 0 17 17 11 11 9 6
Neurotoxicity 25 25 33 0 50 0 50 0 78 0 53 3
Dyspnea 25 0 0 0 25 9 0 0 33 0 21 3
ALT increase 25 0 33 0 25 9 33 17 11 0 24 6
AST increase 0 25 33 0 25 17 50 0 11 0 24 9
Hyponatremia 75 0 67 0 33 17 0 17 11 0 29 9
Fatigue 50 25 67 33 58 17 67 0 67 22 62 18
Hypertension 0 50 33 0 50 0 33 50 44 22 38 21
DL dose level, RS reverse sequence, G grade, LVEF left ventricular ejection fraction, AST aspartate aminotransferase, ALT
alanine aminotransferase
a One patient of 13 in DL1 could not be analyzed for toxicity. The safety population included 34 patients
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The safety profile of cisplatin is well known,
with renal, gastrointestinal toxicity, and
neuropathy. When used as a single agent,
pazopanib is considered reasonably tolerated.
The first dose-finding study in patients with
cancer that yielded the recommendation of the
800-mg daily dose showed limited toxicity, the
most frequent being hypertension [24]. In renal
cell carcinoma, pazopanib compared to
sunitinib appeared to be better tolerated with
a few G3 or 4 adverse events [25]. In medullary
thyroid carcinoma, G3 or 4 toxicities were
infrequent, consisting mostly of fatigue (14%)
or diarrhea (9%) [9]. In breast cancer, 14% of
patients had G3 or 4 hepatic enzymes increases,
14% had G3 or 4 neutropenia, and 14% had G3
hypertension [11].
Several studies have investigated pazopanib
and cytotoxic drugs combination. In the phase I
dose-escalation study of pazopanib combined
with gemcitabine, the MTD could not be
determined, since no DLTs were observed at
the highest DL, pazopanib 800 mg and
gemcitabine 1250 mg/day, i.e., doses used as
single agent for each drug [12]. Most frequent
adverse events were fatigue, nausea, anorexia,
and decreased leucocytes. One-third of patients
experienced G4 neutropenia or
thrombocytopenia.
The combination with pemetrexed was
explored in a phase I study in 25 patients with
advanced solid tumors after failure of standard
therapy [13]. The MTD was pazopanib 800 mg
daily and pemetrexed 500 mg/m2 q3W; 44% of
patients experienced G4 neutropenia at some
point during the study. Two patients out of 20,
both with NSCLC, had partial response. These
promising results led to perform a phase II trial
of pazopanib ? pemetrexed compared to
cisplatin ? pemetrexed in NSCLC [14]. This
trial was discontinued prematurely due to
unacceptable toxicity in the
pazopanib ? pemetrexed arm (3 toxic deaths
among 61 patients).
Interestingly, pazopanib was safe in
combination with continuous infusion of
ifosfamide, since doses up to 1000 mg could be
administered without major toxicity [26].
However, the same combination with
administration of ifosfamide in bolus was
poorly tolerated and pazopanib had to be
decreased to 200 mg.
A phase I trial showed that pazopanib
800 mg daily and paclitaxel 80 mg/m2 at day
1, 8, and 15 in 28-day cycles was feasible [15].
Most frequent G3 or 4 toxicities were liver
enzymes increases and neutropenia. The
response rate was 19%. Another study assessed
the same combination with paclitaxel every
21 days in 26 patients confirmed a manageable
safety profile with the same toxicities [16]. The
MTD was pazopanib 800 mg ? paclitaxel
150 mg/m2.
The 3-drug combination paclitaxel ?
carboplatin ? pazopanib was poorly tolerated
(mainly hematologic toxicity) at standard doses
in a phase I, dose-finding study [17]. The MTD
was pazopanib 200 mg, paclitaxel 175 mg/m2,
and carboplatin AUC 5. Concurrent
administration of pazopanib increased
significantly the exposure to paclitaxel and
carboplatin, which could explain the greatest
toxicity. Among 34 patients, 2 and 4 had
complete and partial responses, respectively,
(17% response rate) and another 7 patients
presented disease stabilization. The same
combination in previously untreated
gynecologic tumors had been estimated not
feasible due to intolerable toxicity, even at the
lowest dose level (pazopanib 400 mg,
carboplatin AUC 5, paclitaxel 175 mg/m2 every
21 days) [27].
Taken together, these results suggest that the
combination of pazopanib with platinum
Oncol Ther (2016) 4:211–223 219
derivatives (or salts) might be more toxic than
expected at the doses explored. PK interactions
may partly explain this finding. We did not find
any impact of pazopanib on cisplatin PKs, in
contrast to the results obtained by Burrris et al.,
who showed that carboplatin AUC was higher
when administered with pazopanib [17].
However, in our study, we showed an
increased exposure to pazopanib with
concomitant cisplatin, likely due to the
interaction with the CYP3A4 inhibitor
aprepitant. The contribution of the decrease in
pazopanib oral clearance by aprepitant to the
poor tolerance observed during this phase I
study should have been limited. Indeed, it
concerns only 3 days of treatment among a
21-day cycle since the half-life elimination of
aprepitant is around 9 h. The pazopanib
concentrations observed at day 0 should be
more representative of the daily exposure of the
patients. The plasma pazopanib exposures
observed at day 0 with a 400-mg dose were
similar to those observed at the recommended
dose of pazopanib in mono-chemotherapy
(800 mg) during the first-in-man phase I study.
The observed pazopanib plasma overexposure
probably contributed to the poor tolerance
encountered during this phase I study.
This study represents the first study revealing
a significant PK interaction between aprepitant
and a TKI. Usually, aprepitant is not
administered in combination with pazopanib,
but is suggested as a prolonged treatment of
pruritus associated with erlotinib [28]. The
current results emphasize the need for further
evaluation of the interaction between
aprepitant and other TKIs.
The combination of platinum-based
chemotherapy and anti-angiogenic
multi-target TKIs carries particularly high
toxicity, as shown by studies with sunitinib
[29–31] or, to a lesser extent with sorafenib
[32, 33] mainly due to overlapping of toxicity
profile of the drugs. Other strategies such as less
toxic chemotherapy or different schedules
(weekly, metronomic) or intermittent dosing
of pazopanib should be explored. Moreover, a
focus on sequential treatment represents an
alternative option as demonstrated recently in
ovarian carcinoma [34]. Further analysis may
identify specific subgroups of patients who may
derive benefit of anti-angiogenic drug.
The choice of cisplatin can be questioned,
due to its high toxicity. Carboplatin is now
preferred in many tumor types, such as ovarian,
cervix or breast cancer. However, at the time of
writing of this protocol, cisplatin was
considered as the leading compound in
platinum-based therapies, particularly in breast
cancer. Initially, this phase I study was designed
to evaluate the combination
cisplatin ? pazopanib for treatment of
advanced triple negative breast cancer in a
planned extension cohort, due to preliminary
results of cisplatin and sunitinib [35, 36] in this
indication. The extension phase has been
canceled when the combination appeared too
toxic to be further explored. However, the
authors acknowledge that the 6 (17%) patients
who had received prior cisplatin before
inclusion in the study may have accounted for
the observed toxicity. Finally, the
administration of aprepitant, despite
predictable interactions with pazopanib, was
considered as it is the standard of care of
patients receiving cisplatin due to the high
emetogenic potential of this cytotoxic drug.
CONCLUSION
Despite clinical activity observed in four
patients, our data show that pazopanib
combined with cisplatin may not be tolerable
at the dose and regimen tested in this study.
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